TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: CID diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic findings of reflux esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Critical Thinking Tendency Scale (CTTS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Muscular Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tendon Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of C. difficile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of patients who complete the full study treatment
Endpoint domain: Mortality/survival
Primary endpoint: Endoscopic complete response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of uterine fibroids volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Keloid Scar Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sleep efficiency for Alzheimer's disease patients
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Total wake time for Alzheimer's disease patients
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Sleep quality for caregivers
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Validity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity to change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of uterine bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Match rate of PD-L1 protein and mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active joint position sense measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: SARS-CoV-2 viral expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HBeAg Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Undetectable HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under Curve [AUC]last of fluconazole in Whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration [Cmax] of fluconazole in Whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of missed adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pathologic Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnosis rate of gastric conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Breast tumor localization accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 21-day incidence of COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: mean time weighted DAS28-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decisional Conflict Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Unified Parkinson's Disease Rating Scale, part III (motor)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: MATRICS - Composite Score t score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 2 or higher oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Peptic Ulcer(s)
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Anagrelide (SPD422)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of 3-Hydroxy (OH)-Anagrelide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Zero to Last Time Point (AUC[0-t]) of Anagrelide (SPD422)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chemotherapy-induced neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: sensitivity of urinalysis by Urine-DNA test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of urinalysis by Urine-DNA test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of positive urine-DNA test results with the next generation sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of alcohol free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average number of drinks per drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: period to relapse to heavy alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: STI Infection Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Nasal nitric oxide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Nitric oxide metabolite (nitrate, nitrite) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of displaced intrauterine devices after insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of Relapse of Acute Myeloid Leukemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Flap Color
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Non-irradiated Tumor Lesions That Had a Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy of ZOMACTON
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TSH Response to TRH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Patient preference for gas
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of adverse events (AE) or serious adverse events (SAE) of CART cell infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Overall response rate (ORR) after infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Precision of mesh detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator Global Assessment (IGA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of Recovery 40 (QoR-40)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Minimal erythema dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Measure of body habitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of radiographic caries progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pulmonary Capillary Wedge Pressure (PCWP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of death of all cause
Endpoint domain: Mortality/survival
Primary endpoint: Number of emergent hospitalization for any cardiovascular reason
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Sleep Difficulty
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Shoulder Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hemoglobin A1C (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MicroRNAs expression level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's assessment of pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Device and Procedure related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical chemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Lyso-glucosylceramide (lyso-GL1) and glucosylceramide (GL-1) levels in cerebrospinal fluid (CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in clinical laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Mean 24-hour Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of chronic breast pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative CT Airway Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of new cases of gastric carcinoma
Endpoint domain: Mortality/survival
Primary endpoint: Change in Hemoglobin (Hb) From Baseline to Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of periprosthetic leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of patients with clinically relevant changes in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Tinetti balance, gait and fall risk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean amplitude glucose excursions (MAGE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in coefficient of variation (CV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in standard deviation (SD) of mean glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of UAI acts with HIV-negative or status unknown partners
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Total Ocular Surface Staining (TOSS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of biomarkers with allograft rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measures of hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Measure the best response under Halaven®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expected Body Weight (EBW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Death
Endpoint domain: Mortality/survival
Primary endpoint: Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with adverse events (AEs) due to AZD9977
Endpoint domain: Adverse events/effects
Primary endpoint: Systolic blood pressure [SBP]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic blood pressure [DBP]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Annual caseload for pediatric liver transplantation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients with HBsAg serological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Electroencephalogram power in alpha band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients developing shopping behavior
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of IgA anti-LPS ASC responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serious and non-serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in bookings and attendance at screenings
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Facilitation of completing a cervical screening
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: DA release in brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with ovarian hyperstimulation syndrome (OHSS)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first acute or progressive neurological event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nighttime wakefulness after persistent sleep onset (WASO)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: unintentional excision rate of parathyroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity of registered level of tie
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of registered level of tie
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BRCA 1/2 germline mutation prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Unbiopsied Lesions That Are Confirmed Positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Complete response index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reliability of subjective qualitative assessment of the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Stent Dwell Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Concentrations of Alkaline phosphatase (ALP) or gamma-glutamyltransferase (γGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hair toxic metal and trace element status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Curve (AUC) 0-21 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-tlast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumen area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax,ss of teneligliptin and empagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ,ss of teneligliptin and empagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: soft tissue health and stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug Concentration Measurement in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Comprehension of research informed consent
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Adverse Childhood Experience (ACE)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression, Anxiety, and Stress Scale (DASS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B, version 4)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Operating Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety (Analysis of Adverse Events)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Cerebrothromboemboli
Endpoint domain: Mortality/survival
Primary endpoint: Change in Neurocognitive Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bleeding Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Heart rate values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Blood pressure values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual Analog Scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Short form 36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: DASS-Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: DASS-Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: DASS-Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Thiobarbituric Reactive Substances (TBARS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in serum homocysteine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anti mullerian Hormone (AMH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Follicle Stimulating Hormone (FSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ovarian Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of the neurologic state measured by the ASIA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: improvement of the strength of trunk muscles measured by the Berg Balance scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of neurologic state measured with tests of deep sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain Atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of teachers' use of emotional and physical violence
Endpoint domain: Adverse events/effects
Primary endpoint: Change of student's exposure to emotional and physical violence by teachers
Endpoint domain: Adverse events/effects
Primary endpoint: Microbial load counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Functional Movement Screen Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tube-feeding related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of hospitalizations due to heart failure worsening
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in NYHA class
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in 6 minute walk test distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of ICU dependency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of WBC's
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decrease of Number of Loose Stools to <3 Per Day Following Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quadriceps Muscle Strength in Kilogram-force (Kgf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Pain Scores Using the Numeric Pain Scoring System (NS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Opioid Consumption at 24 Hours Post-block
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in Social Functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in Social Engagement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: infusion-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Response to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Activities Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Grade 3 and Above Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Time With Sensed Glucose < 70 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes